NZ600125A - Methods of treating or preventing acute erythema - Google Patents

Methods of treating or preventing acute erythema

Info

Publication number
NZ600125A
NZ600125A NZ60012510A NZ60012510A NZ600125A NZ 600125 A NZ600125 A NZ 600125A NZ 60012510 A NZ60012510 A NZ 60012510A NZ 60012510 A NZ60012510 A NZ 60012510A NZ 600125 A NZ600125 A NZ 600125A
Authority
NZ
New Zealand
Prior art keywords
alpha adrenergic
treating
acute erythema
receptor agonist
adrenergic receptor
Prior art date
Application number
NZ60012510A
Other languages
English (en)
Inventor
Philippe Andres
Christian Loesche
Michael Graeber
Original Assignee
Galderma Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa
Publication of NZ600125A publication Critical patent/NZ600125A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ60012510A 2009-10-26 2010-10-19 Methods of treating or preventing acute erythema NZ600125A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25480509P 2009-10-26 2009-10-26
PCT/US2010/053198 WO2011053487A1 (en) 2009-10-26 2010-10-19 Methods of treating or preventing acute erythema

Publications (1)

Publication Number Publication Date
NZ600125A true NZ600125A (en) 2014-05-30

Family

ID=43922456

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60012510A NZ600125A (en) 2009-10-26 2010-10-19 Methods of treating or preventing acute erythema

Country Status (12)

Country Link
US (1) US20110224216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2493309A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013508454A (cg-RX-API-DMAC7.html)
KR (1) KR20120125230A (cg-RX-API-DMAC7.html)
CN (1) CN102711471A (cg-RX-API-DMAC7.html)
AU (1) AU2010313643B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012009891A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779063A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012004890A (cg-RX-API-DMAC7.html)
NZ (1) NZ600125A (cg-RX-API-DMAC7.html)
RU (1) RU2012122983A (cg-RX-API-DMAC7.html)
WO (1) WO2011053487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (ru) * 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EP2994120B1 (en) * 2013-05-06 2019-10-09 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
EP2962689B1 (en) * 2014-06-30 2018-04-11 Galderma S.A. Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
CN106361733A (zh) * 2015-07-22 2017-02-01 刘里远 外用经穴激动剂
US10617688B2 (en) 2016-03-22 2020-04-14 Doris Maria HEXSEL Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
FR3119986B1 (fr) * 2021-02-19 2024-02-16 Tarian Pharma Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911196B2 (en) * 2002-07-31 2005-06-28 Samir I. Hamtini Topical medicament for treating nappy rash
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050226899A1 (en) * 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US7709014B2 (en) * 2005-10-17 2010-05-04 Yu Ruey J Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
CN103298472A (zh) * 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US20120101104A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel compositions and methods of use
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
BR112012009891A2 (pt) 2015-09-29
WO2011053487A1 (en) 2011-05-05
CN102711471A (zh) 2012-10-03
AU2010313643B2 (en) 2015-11-12
EP2493309A1 (en) 2012-09-05
KR20120125230A (ko) 2012-11-14
AU2010313643A1 (en) 2012-06-07
JP2013508454A (ja) 2013-03-07
EP2493309A4 (en) 2013-05-01
RU2012122983A (ru) 2014-01-27
US20110224216A1 (en) 2011-09-15
CA2779063A1 (en) 2011-05-05
MX2012004890A (es) 2012-09-28

Similar Documents

Publication Publication Date Title
MX2012004134A (es) Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.
WO2009129433A3 (en) Alpha adrenergic receptor agonists for treatment of degenerative disc disease
BR112012012131A2 (pt) uso de agonistas de receptores adrenérgicos alfa-2 para tratar ou prevenir psoríase
WO2009129494A3 (en) Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
EP2559434A3 (en) Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BR112012009891A2 (pt) métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
PH12013500221A1 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2012047645A3 (en) Combination treatment for rosacea
RU2013125042A (ru) Способ предотвращения или лечения опухоли кожи
WO2018060463A3 (en) Treatment of prostate cancer
EA201690895A1 (ru) Офтальмологический раствор тартрата бримонидина для местного применения
BR112013001422A2 (pt) metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
BRPI0808327A2 (pt) "aparelho de spinner para facilitar a conexão e desconexão de tubulares encadeados e método para facilitar a conexão e desconexão dos tubulares encadeados"
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
WO2009052073A3 (en) Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009129491A3 (en) Beta adrenergic receptor agonists for treatment of pain and/or inflammation
TN2011000457A1 (en) Method or system using biomarkers for the monitoring of a treatment

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2017 BY CPA GLOBAL

Effective date: 20140908

LAPS Patent lapsed